Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …

Purpose Death from noncancer causes (competing mortality) is an important event in head
and neck cancer, but studies identifying predictors of this event are lacking. We sought to …

One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to
reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike …

This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …

Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …

Background The literature on first generation COVID-19 vaccines show they were less effective
against new SARS-CoV-2 variants of concern including Omicron (BA.1, BA.2, BA.4 and …

Background COVID-19 vaccines with alternative strain compositions are needed to provide
broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed …

… Walsh, MD, 3, * Aiying Chen, PhD, 1 Nicole Grunenberg, MD, 4 Mary Allen, MS, 5
Johannes Antony, PhD, 6 Kwaku Poku Asante, PhD, 7 Amit Suresh Bhate, MD, 8 Tatiana …

Radiation therapy plays an important role in both curative and palliative cancer treatment.
Palliative radiation therapy is given to alleviate symptoms, restore function, relieve suffering …

Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …